Orexigen expects 2nd half Contrave resubmission; Arena seeks European, Chinese partners
This article was originally published in Scrip
If all goes well, Orexigen Therapeutics could resubmit its new drug application (NDA) for its antiobesity medicine Contrave (naltrexone SR/bupropion SR) to the US FDA in the second half of this year, with the potential the firm could finally gain approval of the drug in early 2014, the company said on 7 January, noting those plans depend on the timing of an interim analysis of its cardiovascular outcomes trial (CVOT).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.